|Videos|September 22, 2020

How COVID-19 Impacted Antibiotic Resistance | Dr. Debra Goff

Dr. Debra Goff describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

Segment Description: Debra Goff, PharmD, describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

COVID-19 Hospital Data Reveal Rush to Antibiotics

Coronavirus disease 2019 (COVID-19) can present with bacterial coinfection, but concerns about antibiotic over-prescription haven’t gone away amid the SARS-CoV-2 pandemic.

Soon after visiting 38 hospitals in Michigan, over half of patients hospitalized with suspected COVID-19 received antibiotics, according to authors of a new study in Clinical Infectious Diseases.

Patients were feared to have a bacterial coinfection alongside COVID-19.

But testing later showed that 96.5% of patients only had the coronavirus, making the antibiotic prescriptions superfluous.

Data were collected between 3/13/2020-6/18/2020.

Out of a total 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy. Only 3.5% (59/1705) had a confirmed community-onset bacterial infection.

Across the 38 hospitals, early empiric antibacterial use varied greatly from 27%-84%.

“Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased,” authors reported.

Despite a low prevalence of confirmed community-onset bacterial coinfection, half of patients received early empiric antibacterial therapy.

Antibiotic prescribing in reaction to the pandemic varied by hospital.

“Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use,” study authors concluded.


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.